These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38531462)
1. Edaravone counteracts redox and metabolic disruptions in an emerging zebrafish model of sporadic ALS. Oliveira NAS; Pinho BR; Pinto J; Guedes de Pinho P; Oliveira JMA Free Radic Biol Med; 2024 May; 217():126-140. PubMed ID: 38531462 [TBL] [Abstract][Full Text] [Related]
2. β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Ojeda I; Martínez A; Gil C; Arahuetes RM Environ Toxicol Pharmacol; 2013 Sep; 36(2):243-255. PubMed ID: 23688553 [TBL] [Abstract][Full Text] [Related]
3. Editor's Highlight: Embryonic Exposure to the Environmental Neurotoxin BMAA Negatively Impacts Early Neuronal Development and Progression of Neurodegeneration in the Sod1-G93R Zebrafish Model of Amyotrophic Lateral Sclerosis. Powers S; Kwok S; Lovejoy E; Lavin T; Sher RB Toxicol Sci; 2017 May; 157(1):129-140. PubMed ID: 28123103 [TBL] [Abstract][Full Text] [Related]
4. The Effects of Long-term, Low-dose β-N-methylamino-L-alanine (BMAA) Exposures in Adult SOD Weeks RD; Banack SA; Howell S; Thunga P; Metcalf JS; Green AJ; Cox PA; Planchart A Neurotox Res; 2023 Oct; 41(5):481-495. PubMed ID: 37552461 [TBL] [Abstract][Full Text] [Related]
5. Zebrafish CCNF and FUS Mediate Stress-Specific Motor Responses. Aksoy YA; Cole AJ; Deng W; Hesselson D Cells; 2024 Feb; 13(5):. PubMed ID: 38474336 [TBL] [Abstract][Full Text] [Related]
6. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse. Ikeda K; Iwasaki Y PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273 [TBL] [Abstract][Full Text] [Related]
7. An explanation for the changes in collagen in sporadic amyotrophic lateral sclerosis. Field NC; Caller TA; Stommel EW Med Hypotheses; 2011 Oct; 77(4):565-7. PubMed ID: 21745715 [TBL] [Abstract][Full Text] [Related]
8. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Bhandari R; Kuhad A; Kuhad A Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226 [TBL] [Abstract][Full Text] [Related]
9. Ultrafine particulate matter pollution and dysfunction of endoplasmic reticulum Ca Sapienza S; Tedeschi V; Apicella B; Pannaccione A; Russo C; Sisalli MJ; Magliocca G; Loffredo S; Secondo A Ecotoxicol Environ Saf; 2024 Mar; 273():116104. PubMed ID: 38377779 [TBL] [Abstract][Full Text] [Related]
10. The activation of Mucolipin TRP channel 1 (TRPML1) protects motor neurons from L-BMAA neurotoxicity by promoting autophagic clearance. Tedeschi V; Petrozziello T; Sisalli MJ; Boscia F; Canzoniero LMT; Secondo A Sci Rep; 2019 Jul; 9(1):10743. PubMed ID: 31341250 [TBL] [Abstract][Full Text] [Related]
11. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Kato S; Kato M; Abe Y; Matsumura T; Nishino T; Aoki M; Itoyama Y; Asayama K; Awaya A; Hirano A; Ohama E Acta Neuropathol; 2005 Aug; 110(2):101-12. PubMed ID: 15983830 [TBL] [Abstract][Full Text] [Related]
12. Chronic BMAA exposure combined with TDP-43 mutation elicits motor neuron dysfunction phenotypes in mice. Arnold FJ; Burns M; Chiu Y; Carvalho J; Nguyen AD; Ralph PC; La Spada AR; Bennett CL Neurobiol Aging; 2023 Jun; 126():44-57. PubMed ID: 36931113 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population. Tomar S; Gupta S; Singal A; Soni R J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425 [TBL] [Abstract][Full Text] [Related]
14. Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC. Spencer PS J Neurol Sci; 2022 Feb; 433():120021. PubMed ID: 34635325 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study. Park JM; Park D; Kim HJ; Park JS BMC Neurol; 2022 Jul; 22(1):260. PubMed ID: 35836136 [TBL] [Abstract][Full Text] [Related]
16. Swimming against ALS: How to model disease in zebrafish for pathophysiological and behavioral studies. Oliveira NAS; Pinho BR; Oliveira JMA Neurosci Biobehav Rev; 2023 May; 148():105138. PubMed ID: 36933816 [TBL] [Abstract][Full Text] [Related]
17. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. Ohta Y; Nomura E; Shang J; Feng T; Huang Y; Liu X; Shi X; Nakano Y; Hishikawa N; Sato K; Takemoto M; Yamashita T; Abe K J Neurosci Res; 2019 May; 97(5):607-619. PubMed ID: 30565312 [TBL] [Abstract][Full Text] [Related]
18. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Li Q; Feng Y; Xue Y; Zhan X; Fu Y; Gui G; Zhou W; Richard JP; Taga A; Li P; Mao X; Maragakis NJ; Ying M Mol Neurodegener; 2022 Jan; 17(1):8. PubMed ID: 35012575 [TBL] [Abstract][Full Text] [Related]
19. Edaravone for the treatment of amyotrophic lateral sclerosis. Yoshino H Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406 [TBL] [Abstract][Full Text] [Related]